In one of the studies, Watson for Oncology AI trained by New York City’s Memorial Sloan Kettering Cancer Center influenced changes in the treatment plans of 13.6 percent of breast, lung and colorectal cancer patients in India. The majority of those cases were altered after Watson identified and suggested newer treatments or more personalized alternatives to the multidisciplinary tumor board at Bengaluru-based Manipal Hospitals.
Another study incorporated Watson for Oncology into the patient engagement and consultation process at the Beijing Chaoyang Integrative Medicine Emergency Medical Center’s oncology department. Physicians reported that the AI helped patients better understand their diagnosis and treatment options, resulting in greater patient confidence in their care plans.
“In this early era of AI use in healthcare decision-making, the studies presented at ASCO this year offer compelling evidence of the important role this technology will play in helping oncologists improve cancer treatment for each individual patient,” Nathan Levitan, MD, chief medical officer for oncology and genomics at IBM Watson Health, said in a statement.
More articles about AI:
Startup using AI, AR to detect Alzheimer’s 10 years before onset raises $6.3M
Precision medicine startup Tempus raises $200M to reach $3.1B valuation
MIT-developed AI glove teaches robots to ‘feel,’ could improve prosthetics
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
